The CBO published a cost estimate of the FDA Reauthorization Act of 2017 that was advanced by the Senate in May. Estimated budgetary impacts are shown in a table. Assuming the bill will be enacted by the end of fiscal year, CBO estimates that implementation would increase collections (which would be recorded as offsets to discretionary spending under the bill) by about $1.7 billion in 2018. Based on the fee levels and the inflation adjustments specified in the bill, CBO estimates FDA would assess about $9 billion in fees over the 2018-2022 period.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
